TGA / PMDA / NMPA · Asia-Pacific
injectable — TGA / PMDA / NMPA regulatory status
injectable regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 106 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 2023/3720 UMBRELLA | Phase 3 | George Institute for | 2023-503316-33-00 |
| ABX-CT-302EU/EAGLE-i | Phase 3 | Advanced Accelerator Applications | 2023-504026-19-01 |
| APHP180588 | Phase 3 | PARItec | 2024-513532-23-00 |
| APHP200011 | Phase 3 | PARItec | 2024-513327-16-00 |
| APHP211034 | Phase 3 | PARItec | 2024-511866-36-00 |
| APHP211035 | Phase 3 | PARItec | 2023-504847-15-00 |
| APHP211046 | Phase 3 | PARItec | 2023-504511-32-00 |
| APHP220668 | Phase 3 | PARItec | 2023-506597-12-00 |
| APHP220670 | Phase 3 | PARItec | 2023-505500-37-00 |
| APHP220672 | Phase 3 | PARItec | 2023-506725-11-00 |
| APHP220676 | Phase 3 | PARItec | 2023-507254-32-00 |
| APHP220797 | Phase 3 | PARItec | 2023-505109-17-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12318401 | Injectable shear-thinning hydrogel containing therapeutic agent for enhanced tumor therapy | US |
| 12102682 | Injectable photothermal hydrogel based on melanin, preparation method, and application thereof | US |
| 11850325 | Injectable, bioadhesive cryogel scaffolds for biomedical uses | US |
| 11446238 | Injectable dendrimer hydrogel nanoparticles | US |
| 11426418 | Injectable long-acting semi-solid gel formulations | US |
| 11219604 | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith | US |
| 11191842 | Injectable thermoresponsive polyelectrolytes | US |
| 3133787 | GELS HOMOGENES INJECTABLES COMPRENANT DE MULTIPLES FORMES D'ACIDE HYALURONIQUE ET LEURS PROCEDES DE FABRICATION | CA |
| 2020094634 | PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS | WO |
| 10561606 | Injectable long-acting local anesthetic semi-solid gel formulations | US |
| 2020017529 | NOVEL THIENOTHIOPHENE COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | US |
| 2020016151 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of injectable?
injectable currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get injectable regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to injectable?
This spoke lists 106 published programs associated with injectable in our pipeline index.